Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Psoriatic Arthritis and NAFLD
NCT06586281Recruiting
- Sponsor
- University of California, San Diego
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of guselkumab in psoriatic arthritis (PsA) and non-alcoholic fatty liver disease (NAFLD), sponsored by University of California, San Diego. Primary endpoint: Change in NAFLD severity at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06586281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586281.